These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15640869)

  • 1. [Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation].
    Luo XL; Wang Y; Tian GS; Fu XX; Wang YY; Wei L; Chen J; Su S; Fan GR
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):284-6. PubMed ID: 15640869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B.
    Moutinho RS; Perez RM; Medina-Pestana JO; Figueiredo MS; Koide S; Alberto FL; Silva AE; Ferraz ML
    J Med Virol; 2006 Oct; 78(10):1284-8. PubMed ID: 16927290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.
    Ayed K; Gorgi Y; Ayed-Jendoubi S; Aouadi H; Sfar I; Najjar T; Ben Abdallah T
    J Infect; 2007 Mar; 54(3):291-7. PubMed ID: 16911832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
    Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
    J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
    Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
    J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical and pathology study of HBV precore mutant infection in chronic HBV patients].
    Zheng X; Yang D; Tang Z
    Zhonghua Gan Zang Bing Za Zhi; 1999 Mar; 7(1):17-9. PubMed ID: 10366977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
    Yuan J; Zhou BP; Gong ZJ; Xu LM; Jiang XL; Mizokami M
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):30-2. PubMed ID: 16642214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
    Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
    AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India.
    Chauhan R; Kazim SN; Bhattacharjee J; Sakhuja P; Sarin SK
    J Med Virol; 2006 Aug; 78(8):1047-54. PubMed ID: 16789012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
    Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
    Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
    Vandepapelière P; Lau GK; Leroux-Roels G; Horsmans Y; Gane E; Tawandee T; Merican MI; Win KM; Trepo C; Cooksley G; Wettendorff M; Ferrari C;
    Vaccine; 2007 Dec; 25(51):8585-97. PubMed ID: 18031872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
    Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
    Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients.
    Huang YH; Wu JC; Chang TT; Sheen IJ; Huo TI; Lee PC; Su CW; Lee SD
    J Viral Hepat; 2006 May; 13(5):336-42. PubMed ID: 16637865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low frequency of precore mutants in anti-hepatitis B e antigen positive subjects with chronic hepatitis B virus infection in Chennai, Southern India.
    Shanmugam S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Shankar EM; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
    J Microbiol Biotechnol; 2008 Oct; 18(10):1722-8. PubMed ID: 18955826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of hepatitis B virus (HBV) vaccination in treating lamivudine-resistant HBV reactivation following hepatitis B surface antigen seroconversion.
    Gérolami R; Borentain P; Colson P; Norguet E; Gérolami A; Tamalet C
    Liver Int; 2007 Dec; 27(10):1417-21. PubMed ID: 18036104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.